Cargando…
UB-311, a novel UBITh(®) amyloid β peptide vaccine for mild Alzheimer's disease
INTRODUCTION: A novel amyloid β (Aβ) synthetic peptide vaccine (UB-311) has been evaluated in a first-in-human trial with patients of mild-to-moderate Alzheimer's disease. We describe translational research covering vaccine design, preclinical characterization, and phase-I clinical trial with s...
Autores principales: | Wang, Chang Yi, Wang, Pei-Ning, Chiu, Ming-Jang, Finstad, Connie L., Lin, Feng, Lynn, Shugene, Tai, Yuan-Hung, De Fang, Xin, Zhao, Kesheng, Hung, Chung-Ho, Tseng, Yiting, Peng, Wen-Jiun, Wang, Jason, Yu, Chih-Chieh, Kuo, Be-Sheng, Frohna, Paul A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651432/ https://www.ncbi.nlm.nih.gov/pubmed/29067332 http://dx.doi.org/10.1016/j.trci.2017.03.005 |
Ejemplares similares
-
A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine
por: Yu, Hui Jing, et al.
Publicado: (2022) -
Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study
por: Yu, Hui Jing, et al.
Publicado: (2023) -
IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms
por: Kuo, Be-Sheng, et al.
Publicado: (2022) -
Mild behavioral impairment is associated with β‐amyloid but not tau or neurodegeneration in cognitively intact elderly individuals
por: Lussier, Firoza Z., et al.
Publicado: (2020) -
The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals
por: Dickerson, Bradford C., et al.
Publicado: (2009)